129 results on '"Nicholas J. Wang"'
Search Results
2. Patient-specific factors influence somatic variation patterns in von Hippel–Lindau disease renal tumours
3. Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes
4. Supplementary Figure 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
5. Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
6. Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers
7. Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
8. Supplementary Figure 3 from Temporal Dissection of Tumorigenesis in Primary Cancers
9. Supplementary Figure 4 from Temporal Dissection of Tumorigenesis in Primary Cancers
10. Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
11. Supplementary Figure 2 from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
12. Data from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
13. Supplementary figure legend from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
14. Supplementary Figure 1 from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
15. Supplemental Tables 1, 2, 3 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
16. Supplemental Figure 6B from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
17. Supplemental Figure 3 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
18. Supplemental Table 8 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
19. Supplemental Table 7 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
20. Supplementary Table 4 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
21. Supplementary Tables 1-3 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
22. Supplemental Figure and Table Legends from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
23. Supplemental Figure 2 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
24. Supplemental Table 6 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
25. Supplementary Figure Legends 1-2 from Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
26. Data from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
27. Supplementary Figure 1 from Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
28. Supplemental Figure 1 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
29. Supplementary Legends for Figures and Tables 1-8 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
30. Supplementary Tables 5-8 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
31. Supplementary Tables 1-6 from Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
32. Supplemental Figure 7 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
33. Supplementary Figure 4 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
34. Supplementary Figures 5 and 6A-B from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
35. Supplemental Figure 8 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
36. Supplemental Table 5 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
37. Supplementary Figure 2 from Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
38. Conflict of Interest Form 1 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
39. Supplemental Figure 5 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
40. Morphometric Subtyping for a Panel of Breast Cancer Cell Lines.
41. Examining ACE analysis reliability estimates using fault-injection.
42. ReStore: Symptom Based Soft Error Detection in Microprocessors.
43. Y-Branches: When You Come to a Fork in the Road, Take It.
44. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer
45. Hardware support for software controlled multithreading.
46. ReStore: Symptom-Based Soft Error Detection in Microprocessors.
47. Sequential Element Design With Built-In Soft Error Resilience.
48. An Experimental Study of Soft Errors in Microprocessors.
49. Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
50. Comparative Genomic Hybridization and Copy Number Abnormalities in Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.